NASDAQ · AAPG
Healthcare · Biotechnology
$13.56
Up+$0.09 (+0.66%)
Updated Nov 3, 2026, 8:31 PM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AAPG
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
AAPG closed at $13.56 after 21 trading sessions, down 7.16% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $14.2268 | $14.2268 | $13.46 | $13.56 | 5.53K |
| Oct 30, 2026 | $14.45 | $14.67 | $13.99 | $14.4565 | 15.92K |
| Oct 29, 2026 | $14.71 | $14.90 | $14.71 | $14.88 | 11.29K |
| Oct 28, 2026 | $15.25 | $15.25 | $14.8792 | $14.985 | 4.71K |
| Oct 27, 2026 | $14.69 | $14.87 | $14.54 | $14.85 | 9.97K |
| Oct 26, 2026 | $15.89 | $15.89 | $15.45 | $15.45 | 3.08K |
| Oct 23, 2026 | $15.30 | $15.44 | $15.21 | $15.44 | 9.38K |
| Oct 22, 2026 | $15.30 | $15.30 | $14.90 | $14.92 | 18.79K |
| Oct 21, 2026 | $16.05 | $16.5499 | $15.79 | $16.34 | 1.49K |
| Oct 20, 2026 | $15.57 | $15.92 | $15.49 | $15.92 | 4.89K |
| Oct 19, 2026 | $15.52 | $15.65 | $15.36 | $15.36 | 3.83K |
| Oct 16, 2026 | $14.80 | $15.53 | $14.80 | $15.37 | 15.09K |
| Oct 15, 2026 | $14.69 | $14.9299 | $14.47 | $14.69 | 8.96K |
| Oct 14, 2026 | $15.06 | $15.06 | $14.84 | $14.85 | 3.37K |
| Oct 13, 2026 | $15.06 | $16.07 | $14.83 | $15.06 | 10.26K |
| Oct 12, 2026 | $15.19 | $15.4551 | $15.19 | $15.31 | 4.7K |
| Oct 9, 2026 | $14.50 | $14.8013 | $14.50 | $14.75 | 1.2K |
| Oct 8, 2026 | $14.89 | $14.89 | $14.455 | $14.55 | 12.02K |
| Oct 7, 2026 | $15.14 | $15.40 | $14.85 | $14.94 | 7.24K |
| Oct 6, 2026 | $15.22 | $16.09 | $15.22 | $16.09 | 14.54K |
| Oct 5, 2026 | $14.76 | $14.79 | $14.58 | $14.605 | 3.59K |
The latest Smart Investors Daily articles mentioning AAPG.
Company
Market Activity
Research & News
AAPG research
Company profile and research snapshot.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Oct 21, 2026
CHICAGO, October 21, 2026--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm’s continued expansion of its biotech offering.
Yahoo · Oct 20, 2026
ROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that lisaftoclax (APG-2575), the Company’s novel Bcl-2 inhibitor, has been granted a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of
Yahoo · Oct 19, 2026
Ascentage Pharma Group International has seen its share price move sharply in recent years, yet the current level still leaves a straightforward question for investors who care about fundamentals. Is the price you see on screen today reasonably aligned with what the business is generating in sales, or has sentiment moved further than the top line can comfortably support? With the stock down 56.4% over the past year, the slide puts fresh focus on whether the present valuation can still be...
Benzinga · Oct 16, 2026
William Blair sees major upside for Ascentage Pharma stock as the cancer drug developer approaches three pivotal trial results in 2027.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AAPG.
